David A. Siegel Phio Pharmaceuticals Corp. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.64 - $2.35 $29,888 - $109,745	-46,700 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.73 - $1.1 $121,180 - $182,600	-166,000 Reduced 78.04%	46,700 $41,000
Q4 2021 Feb 14, 2022	BUY	$0.99 - $1.99 $59,004 - $118,604	59,600 Added 38.93%	212,700 $213,000
Q3 2021 Nov 15, 2021	BUY	$1.62 - $2.28 $154,710 - $217,739	95,500 Added 165.8%	153,100 $311,000
Q2 2021 Aug 16, 2021	BUY	$1.87 - $2.8 $52,547 - $78,680	28,100 Added 95.25%	57,600 $130,000

Q1 2021 May 17, 2021	SELL	$2.48 - $4.05 $94,736 - $154,710	-38,200 Reduced 56.43%	29,500 $79,000
Q4 2020 Feb 16, 2021	BUY	$2.01 - $3.32 $136,077 - $224,764	67,700 New	67,700 $182,000

Ticker PHIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,658,700
Market Cap $8.33M
Description
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.